Omega-3 polyunsaturated fatty acids represent a family of essential lipids for numerous biological processes. In the human diet, the plant-based precursor of the omega-3 series is alpha-linolenic acid (ALA), while the most studied long-chain fatty acids are eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA).
ALA is considered essential because the human body is unable to synthesize it in sufficient quantities and it must therefore be introduced through food. From ALA, the body can produce EPA and DHA through a series of desaturation and elongation reactions. However, in humans, the conversion to EPA is relatively limited and that to DHA even more modest. For this reason, from a nutritional and physiological point of view, the direct intake of EPA and DHA can take on particular importance.
EPA and DHA do not simply perform an energy function. They enter the composition of cell membranes, influencing their fluidity, molecular organization, and ability to respond to extracellular signals. DHA, in particular, is an important component of neuronal and retinal membranes, while EPA plays a significant role in the regulation of lipid mediator production.
Omega-3s interact metabolically with the omega-6 fatty acid family. Omega-6s are also essential nutrients and perform important physiological functions. Their main dietary precursor is linoleic acid, from which other polyunsaturated fatty acids can originate through successive transformations, including arachidonic acid.
For many years, the quantitative ratio between omega-6 and omega-3 was considered an important indicator of diet quality. Today, the scientific literature tends to consider this parameter with greater caution: there is no single ratio universally recognized as optimal for all people and all clinical conditions. More important than the simple numerical ratio is probably the overall quality of the diet, the absolute amount of EPA and DHA consumed, and the individual lipid profile.
Arachidonic acid and EPA can be used as substrates for the synthesis of numerous lipid mediators. From these molecules derive prostaglandins, thromboxanes, leukotrienes, and other compounds involved in the regulation of inflammation, vascular function, platelet aggregation, and immune responses.
The traditional distinction between omega-6-derived mediators as exclusively pro-inflammatory and omega-3-derived ones as exclusively anti-inflammatory is, however, an oversimplification. Inflammation is a complex biological process necessary for the body's defense. Omega-3s contribute above all to the modulation and resolution of the inflammatory response.
EPA and DHA can indeed be transformed into specialized pro-resolving mediators, including resolvins, protectins, and maresins. These molecules do not simply act by blocking inflammation, but contribute to the physiological mechanisms through which the inflammatory response is regulated and progressively resolved.
One of the main research fields of omega-3s concerns the cardiovascular system. Heart cell membranes contain polyunsaturated fatty acids that can influence the function of ion channels, the transmission of electrical signals, and the stability of cell membranes.
Experimental studies have suggested that EPA and DHA can influence the electrical excitability of cardiac myocytes and some mechanisms involved in the onset of arrhythmias. Over the years, these biological effects have led to the hypothesis of a possible protective role against sudden cardiac death.
Among the historically most important studies is GISSI-Prevenzione, published at the end of the 1990s. The study involved over 11,000 patients who survived a recent myocardial infarction and contributed significantly to the spread of scientific interest in omega-3s in the cardiovascular field. In the studied population, supplementation with omega-3 fatty acids was associated with a reduction in some cardiovascular endpoints and mortality.
However, it is important to interpret these results in their historical and clinical context. Cardiovascular therapy has changed profoundly in recent decades, with a greater spread of statins, antihypertensive drugs, antiplatelet drugs, and revascularization procedures. Consequently, the results of the most recent studies do not always coincide with those of previous trials.
Contemporary studies therefore suggest that the cardiovascular effects of omega-3s cannot be considered uniform for all formulations, all doses, and all populations. An important distinction concerns general cardiovascular prevention and the treatment of hypertriglyceridemia.
The most consolidated evidence concerns the ability of EPA and DHA to reduce triglyceride levels when used at adequate doses. This effect depends on several mechanisms, including the modulation of hepatic synthesis of triglyceride-rich lipoproteins, the increase in fatty acid oxidation, and changes in lipoprotein metabolism.
In people with high triglycerides, concentrated omega-3 preparations can therefore have a clinically relevant metabolic effect. However, the choice of product, dose, and possible pharmacological treatment must be made based on the individual condition and under medical supervision.
The REDUCE-IT study has aroused particular interest, which evaluated a purified formulation of EPA in patients at high cardiovascular risk with persistently high triglycerides despite statin therapy. The study showed a significant reduction in cardiovascular events in the treated group. However, other large studies conducted with different formulations containing combinations of EPA and DHA did not obtain comparable results.
This set of evidence demonstrates a fundamental principle of nutritional and pharmacological research: it is not correct to consider all omega-3s as an identical intervention. The composition of the formulation, the dose, the concentration of EPA and DHA, and the treated population can significantly modify the clinical outcome.
Omega-3s are also studied for their ability to influence several markers of metabolic syndrome. EPA and DHA can reduce triglycerides and influence endothelial function, hepatic metabolism, and some molecular pathways involved in the inflammatory response.
A randomized clinical study conducted on postmenopausal women with metabolic syndrome observed, after omega-3 supplementation, favorable changes in some metabolic parameters, including triglycerides, blood pressure, insulin resistance, and interleukin-6. The results are biologically interesting, although the response to omega-3s can vary depending on the individual metabolic profile.
The modulation of inflammation by omega-3s involves numerous cellular mechanisms. EPA and DHA can influence the activity of transcription factors, including NF-κB, and modify the expression of genes involved in the production of cytokines and inflammatory mediators.
Furthermore, omega-3s can modify the composition of immune cell membranes and the organization of so-called lipid rafts, specialized cell membrane structures involved in signal transmission.
These mechanisms explain why scientific interest in EPA and DHA extends to numerous conditions characterized by metabolic alterations or a persistent inflammatory response. However, the existence of biologically plausible mechanisms does not automatically mean that supplementation produces proven clinical benefits in all diseases.
Another fundamental field is represented by the nervous system. The human brain is particularly rich in lipids and DHA constitutes an important structural component of neuronal membranes. Its presence can influence membrane fluidity, synapse function, neurotransmission, and intracellular signaling.
During development, DHA plays a particularly important role in the maturation of the nervous system and the retina. In adulthood and old age, research has focused on the possibility that an adequate omega-3 nutritional status can contribute to the maintenance of brain function.
A randomized, placebo-controlled study conducted in healthy subjects aged 50 to 75 years evaluated the effect of omega-3 supplementation on cognitive functions and neuroimaging parameters. The authors observed improvements in some executive function tests and changes in brain structural and vascular parameters.
These results are interesting, but must be interpreted within the overall framework of the evidence. The available meta-analyses do not, in fact, uniformly demonstrate that omega-3 supplementation improves cognitive performance in all healthy populations or reliably prevents dementia.
It is possible that the effects depend on the baseline nutritional status, age, the presence of cognitive deficits, the duration of the intervention, and the amount of DHA and EPA actually available in the tissues.
Brain nutrition does not depend on a single nutrient. Physical activity, sleep, blood pressure, glycemic control, education, cognitive stimulation, and overall diet quality interact with each other in determining brain health throughout life.
The omega-3 Index, which measures the percentage of EPA and DHA present in erythrocyte membranes, represents a tool used in research to assess the individual biological status relative to these fatty acids. Unlike the simple assessment of dietary intake, this index can provide information on the actual incorporation of EPA and DHA into cell membranes.
The individual response to supplementation can be highly variable. People who consume the same amount of omega-3s can reach different tissue concentrations depending on genetics, diet, metabolism, body weight, and microbiota composition.
For this reason, a modern interpretation of nutrition based on individual biology tends to move beyond the concept that all subjects should consume identical amounts of a given nutrient.
The main dietary sources of EPA and DHA are traditionally represented by fish and some marine organisms. However, there are also sources of DHA and EPA obtained from microalgae, particularly interesting for those who follow a vegetarian or vegan diet.
Plant sources such as flaxseeds, chia seeds, walnuts, and some vegetable oils mainly provide ALA. These foods are nutritionally valuable, but should not automatically be considered equivalent to a direct intake of EPA and DHA, considering the limited metabolic conversion of ALA in humans.
A diet based mainly on plants can be nutritionally adequate from the omega-3 point of view as well, provided it is correctly planned and attention is paid to ALA sources and, when appropriate, the nutritional status relative to EPA and DHA.
Omega-3 supplementation must be considered in the overall context of health status. The quantities used for simple nutritional support are not necessarily comparable to the doses studied for triglyceride reduction or in specific clinical protocols.
Safety also requires an appropriate assessment. Omega-3s are generally well tolerated, but at high doses they can cause gastrointestinal disorders and require particular attention in people who take anticoagulant or antiplatelet drugs. Some studies conducted with high doses of specific formulations have also reported an increase in the incidence of atrial fibrillation in certain populations.
For this reason, especially in the presence of cardiovascular diseases, arrhythmias, or pharmacological therapies, the use of concentrated EPA and DHA supplements should be discussed with a doctor.
Omega-3 fatty acids therefore represent an important example of how modern nutrition cannot be reduced to the simple opposition between “good” substances and “bad” substances. EPA, DHA, and ALA participate in complex biological networks and their effect depends on the amount introduced, the metabolic context, the overall quality of the diet, and individual characteristics.
Scientific evidence particularly strongly supports the role of omega-3s in cellular physiology and triglyceride reduction, while the effects on cardiovascular prevention, systemic inflammation, and cognitive functions must be interpreted more specifically in relation to the population, the formulation, and the dose used.
A health-oriented nutritional strategy should therefore not focus exclusively on increasing a single nutrient, but favor an overall balanced dietary model, rich in plant foods, fiber, appropriate sources of unsaturated fats, and characterized by an adequate intake of essential nutrients.
NOTE: The information in the product sheets on this site is for exclusively informative and educational purposes and does not represent a medical opinion. The published content is not intended to replace the relationship with a doctor or any medical indications, diagnoses, or prescriptions. The reported information describes the ingredients and characteristics of food supplements, designed as support for the balance and well-being of the body within a healthy lifestyle. Food supplements are not medicines and must not be used to prevent, diagnose, treat, or alleviate diseases or pathological conditions.
PRODUCT_ITEM
Bibliography
Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2(8666):757-761.
de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343(8911):1454-1459.
GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction. Lancet. 1999;354(9177):447-455.
Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA. 1998;279(1):23-28.
Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995;274(17):1363-1367.
Tardivo AP, Nahas-Neto J, Orsatti CL, Dias FB, Poloni PF, Schmitt EB, Nahas EA. Effects of omega-3 on metabolic markers in postmenopausal women with metabolic syndrome. Climacteric. 2015;18(2):290-298.
Witte AV, Kerti L, Hermannstädter HM, et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cerebral Cortex. 2014;24(11):3059-3068.
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine. 2019;380:11-22.
Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events. JAMA. 2020;324(22):2268-2280.
Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions. 2017;45(5):1105-1115.
Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510:92-101.
Abeywardena MY, Patten GS. Role of omega-3 long-chain polyunsaturated fatty acids in reducing cardiac arrhythmias. International Journal of Cardiology. 2011;154(1):5-14.
